DK1420769T3 - Lipid profil modulation med steroider og PPAR alpha agonister - Google Patents
Lipid profil modulation med steroider og PPAR alpha agonisterInfo
- Publication number
- DK1420769T3 DK1420769T3 DK02707001T DK02707001T DK1420769T3 DK 1420769 T3 DK1420769 T3 DK 1420769T3 DK 02707001 T DK02707001 T DK 02707001T DK 02707001 T DK02707001 T DK 02707001T DK 1420769 T3 DK1420769 T3 DK 1420769T3
- Authority
- DK
- Denmark
- Prior art keywords
- steroids
- lipid profile
- ppar alpha
- alpha agonists
- profile modulation
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 102000023984 PPAR alpha Human genes 0.000 title 1
- 108010028924 PPAR alpha Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 abstract 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 abstract 1
- 230000000778 atheroprotective effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0107383.2A GB0107383D0 (en) | 2001-03-23 | 2001-03-23 | Lipid profile modulation |
| PCT/GB2002/001457 WO2002076435A2 (en) | 2001-03-23 | 2002-03-25 | Lipid profile modulation with steroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1420769T3 true DK1420769T3 (da) | 2008-09-29 |
Family
ID=9911465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02707001T DK1420769T3 (da) | 2001-03-23 | 2002-03-25 | Lipid profil modulation med steroider og PPAR alpha agonister |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050032761A1 (da) |
| EP (1) | EP1420769B1 (da) |
| JP (1) | JP2004528308A (da) |
| AT (1) | ATE397922T1 (da) |
| AU (1) | AU2002241160A1 (da) |
| CA (1) | CA2441834C (da) |
| DE (1) | DE60227080D1 (da) |
| DK (1) | DK1420769T3 (da) |
| ES (1) | ES2307729T3 (da) |
| GB (2) | GB0107383D0 (da) |
| PT (1) | PT1420769E (da) |
| WO (1) | WO2002076435A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258168B2 (en) | 2001-07-27 | 2007-08-21 | Enventure Global Technology L.L.C. | Liner hanger with slip joint sealing members and method of use |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| EP1854487A3 (en) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| EP1615667A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| ATE416761T1 (de) * | 2003-09-22 | 2008-12-15 | Onepharm Res & Dev Gmbh | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund |
| WO2006106052A1 (en) | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| WO2007058346A1 (ja) | 2005-11-21 | 2007-05-24 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| AU2007207055B2 (en) | 2006-01-18 | 2011-06-02 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-HSD1 inhibitors |
| JP2009531712A (ja) * | 2006-03-23 | 2009-09-03 | デ グスマン ブレイヤー、エメリタ | アポリポタンパク質フィンガープリント技術 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| DK2163543T3 (da) | 2007-05-18 | 2015-04-27 | Shionogi & Co | Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet |
| MX2011005037A (es) | 2008-11-21 | 2011-06-16 | High Point Pharmaceuticals Llc | Compuestos de adamantilo benzamida. |
| WO2011061749A2 (en) * | 2009-11-19 | 2011-05-26 | Ganga Raju Gokaraju | Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
| US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
| US9781909B2 (en) * | 2013-07-17 | 2017-10-10 | University Of Manitoba | Mito-Ob: a transgenic mouse model for obesity |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| US10226474B2 (en) * | 2017-01-09 | 2019-03-12 | Temple University—Of The Commonwealth Sytem Of Higher Education | Methods and compositions for treatment of non-alcoholic steatohepatitis |
| KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| AU2023273030A1 (en) | 2022-05-16 | 2024-11-07 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| JP2004502432A (ja) * | 2000-07-05 | 2004-01-29 | バイエル アクチェンゲゼルシャフト | ヒト１１β−ヒドロキシステロイドデヒドロゲナーゼ１様酵素の調節 |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
-
2001
- 2001-03-23 GB GBGB0107383.2A patent/GB0107383D0/en not_active Ceased
-
2002
- 2002-03-25 AT AT02707001T patent/ATE397922T1/de active
- 2002-03-25 JP JP2002574951A patent/JP2004528308A/ja active Pending
- 2002-03-25 PT PT02707001T patent/PT1420769E/pt unknown
- 2002-03-25 ES ES02707001T patent/ES2307729T3/es not_active Expired - Lifetime
- 2002-03-25 DE DE60227080T patent/DE60227080D1/de not_active Expired - Lifetime
- 2002-03-25 AU AU2002241160A patent/AU2002241160A1/en not_active Abandoned
- 2002-03-25 DK DK02707001T patent/DK1420769T3/da active
- 2002-03-25 GB GB0323962A patent/GB2390367B/en not_active Expired - Fee Related
- 2002-03-25 EP EP02707001A patent/EP1420769B1/en not_active Expired - Lifetime
- 2002-03-25 CA CA2441834A patent/CA2441834C/en not_active Expired - Fee Related
- 2002-03-25 WO PCT/GB2002/001457 patent/WO2002076435A2/en not_active Ceased
-
2003
- 2003-09-23 US US10/668,564 patent/US20050032761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1420769A2 (en) | 2004-05-26 |
| GB2390367A (en) | 2004-01-07 |
| CA2441834C (en) | 2011-01-25 |
| JP2004528308A (ja) | 2004-09-16 |
| DE60227080D1 (de) | 2008-07-24 |
| WO2002076435A2 (en) | 2002-10-03 |
| US20050032761A1 (en) | 2005-02-10 |
| GB0107383D0 (en) | 2001-05-16 |
| WO2002076435A3 (en) | 2004-03-18 |
| PT1420769E (pt) | 2008-08-05 |
| EP1420769B1 (en) | 2008-06-11 |
| GB2390367B (en) | 2005-04-13 |
| ATE397922T1 (de) | 2008-07-15 |
| CA2441834A1 (en) | 2002-10-03 |
| ES2307729T3 (es) | 2008-12-01 |
| GB0323962D0 (en) | 2003-11-19 |
| AU2002241160A1 (en) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1420769E (pt) | Modulação de perfil lipídico com esteróides e agonistas de ppar alfa | |
| DE60217233D1 (de) | Abdichtung für Verdichter und Kreiselverdichter mit dieser Abdichtung | |
| ATE424560T1 (de) | Marker für neuromyelitis optica | |
| NO20040865L (no) | Friksjon reduserende sammensetning og metode | |
| ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
| DE60122216D1 (de) | Zolpidem Hemitartrat Solvat | |
| PH12022552267A1 (en) | Tie2-binding agents and methods of use | |
| NO20062649L (no) | Biarylsulfonamider og metoder for anvendelse av disse | |
| ITRM20020105A0 (it) | Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego. | |
| NO20040542L (no) | Fremgangsmate for installasjon av en ankerline og kobling for bruk i fremgangsmaten | |
| PT1553942E (pt) | Composicao farmaceutica associando tenatoprazol e um anti-inflamatorio | |
| DK1509492T3 (da) | Sedative hypnotiske midler med kort virkningsvarighed til anæstesi og sedation | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| NO20040055L (no) | Sarbandasje | |
| ITMI20021822A1 (it) | Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico | |
| UY28531A1 (es) | Composición líquida biologicamente estable de fviii, de fww o del complejo fviii/fww humanos | |
| NO20043107L (no) | Bronnsementeringsbestanddeler for kalde omgivelser | |
| IS7275A (is) | Samsetning fyrir hollegg og notkun á henni | |
| NO20033747D0 (no) | Fremgangsmåte ved sementering i en underjordisk sone og brönnsement til bruk ved utförelse av fremgangsmåten | |
| FI20031191A7 (fi) | Monoamiinin takaisinoton estäjä | |
| MXPA04007387A (es) | El empleo de inhibidores del intercambiador de sodio/hidrogeno para el tratamiento de desordenes tromboticos e inflamatorios. | |
| ITRM20050478A1 (it) | Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia. | |
| NO20044186L (no) | Peptid-deformylaseinhibitorer | |
| ATE433953T1 (de) | Peptiddeformylaseinhibitoren | |
| TW200500012A (en) | Novel lactobacillus and use thereof |